**Table 1:** Participants characteristics according the diabetes status and LV function

|  |  |  |
| --- | --- | --- |
| Variable | No diabetes ( N= 208,566) | Diabetes (N= 52,160) |
| Good LV | Moderate LV | Poor LV | p-value | Good LV | Moderate LV | Poor LV | p-value |
| Mean age | 64±11 | 67±12 | 68±12 | <0.001 | 65±11 | 68±11 | 69±11 | <0.001 |
| Male sex | 114,676 (74%) | 30,051 (76%) | 10,112 (77%) | <0.001 | 25,005 (71%) | 8,715 (74%) | 3,784 (76%) | <0.001 |
| Smoking statusNeverEx-smokerCurrent smoker | 52,341 (36%)60,888 (42%)31,742 (22%) | 11,498 (32%)15,264 (42%)9,171 (26%) | 3,730 (33%)4,944 (44%)2,632 (23%) | <0.001 | 12,718 (39%)15,149 (46%)4,942 (15%) | 3,739 (35%)5,425 (49%)1,737 (16%) | 1,486 (34%)2,132 (49%)702 (16%) | <0.001 |
| Hypertension | 82,283 (54%) | 20,444 (53%) | 6,888 (53%) | 0.021 | 25,836 (74%) | 8,641 (74%) | 3,609 (73%) | 0.25 |
| Hypercholesterolemia | 93,693 (61%) | 22,571 (59%) | 7,345 (57%) | <0.001 | 25,491 (73%) | 8,523 (73%) | 3,469 (70%) | <0.001 |
| Family history of CAD | 68,608 (48%) | 15,694 (45%) | 4,445 (41%) | <0.001 | 15,752 (49%) | 5,048 (49%) | 1,932 (47%) | 0.08 |
| Previous MI | 35,010 (24%) | 14,666 (41%) | 5,223 (44%) | <0.001 | 10,546 (32%) | 5,841 (54%) | 2,681 (59%) | <0.001 |
| Renal disease | 2,058 (1%) | 1,162 (3%) | 774 (6%) | <0.001 | 1,513 (4%) | 1,063 (9%) | 705 (14%) | <0.001 |
| Previous PCI | 34,058 (22%) | 9,205 (24%) | 2,924 (23%) | <0.001 | 10,697 (31%) | 3,845 (33%) | 1,449 (30%) | <0.001 |
| Previous CABG | 9,707 (6%) | 4,232 (11%) | 1,440 (12%) | <0.001 | 3,936 (11%) | 2,408 (21%) | 923 (19%) | <0.001 |
| Intra-aortic balloon pump use | 693 (0.5%) | 965 (3%) | 1,322 (10%) | <0.001 | 167 (0.5%) | 309 (2.7%) | 512 (10.6%) | <0.001 |
| Pre-procedural ventilation | 754 (0.6%) | 723 (2%) | 668 (6%) | <0.001 | 140 (0.5%) | 191 (1.8%) | 247 (5.4%) | <0.001 |
| Cardiogenic shock | 981 (0.7%) | 1,217 (3%) | 1,530 (12%) | <0.001 | 166 (0.5%) | 340 (3.0%) | 608 (12.6%) | <0.001 |
| Thrombolysis use | 1,232 (0.8%) | 957 (3%) | 293 (2%) | <0.001 | 161 (0.5%) | 140 (1%) | 72 (1%) | <0.001 |
| Radial access | 75,165 (50%) | 18,840 (49%) | 5,481 (43%) | <0.001 | 17,086 (50%) | 5,442 (47%) | 1,961 (40%) | <0.001 |
| DiagnosisUnstable anginaNSTEMISTEMI | 78,535 (52%)57,617 (38%)14,877 (10%) | 11,259 (30%)17,515 (47%)8,363 (23%) | 4,061 (33%)5,347 (44%)2,812 (23%) | <0.001 | 19,667 (57%)12,497 (36%)2,211 (6%) | 4,143 (36%)5,713 (50%)1,532 (13%) | 1,567 (33%)2,378 (51%)750 (16%) | <0.001 |
| Vessel attemptedLADLeft mainCircumflexRCAGraft | 74,328 (49%)4,604 (3%)38,745 (25%)57,103 (38%)4,182 (3%) | 20,175 (52%)2,001 (5%)9,345 (24%)12,560 (32%)1,948 (5%) | 7,059 (55%)1,134 (9%)3,299 (26%)3,942 (31%)585 (5%) | <0.001<0.001<0.001<0.001<0.001 | 15,944 (46%)1,324 (4%)9,599 (28%)12,997 (38%)1,429 (4%) | 5,514 (47%)783 (7%)3,240 (28%)3,753 (32%)989 (8%) | 2,507 (51%)517 (11%)1,423 (29%)1,521 (31%)384 (8%) | <0.001<0.0010.23<0.001<0.001 |
| Three vessel disease | 9,228 (6%) | 4,547 (12%) | 2,239 (17%) | <0.001 | 3,261 (9%) | 2,252 (19%) | 1,257 (26%) | <0.001 |
| Bare metal stent | 31,554 (21%) | 9,841 (26%) | 3,698 (29%) | <0.001 | 5,209 (15%) | 2,153 (19%) | 1,084 (22%) | <0.001 |
| No. of stents | 1.46±0.98 | 1.50±1.00 | 1.51±1.06 | <0.001 | 1.48±1.03 | 1.52 ±1.07 | 1.59±1.13 | <0.001 |
| Death at 30 days | 952 (0.6%) | 1,139 (2.9%) | 1,335 (10.2%) | <0.001 | 326 (0.9%) | 438 (3.7%) | 597 (12.0%) | <0.001 |
| In-hospital MACE | 1,898 (1.2%) | 1,079 (2.7%) | 1,031 (7.8%) | <0.001 | 457 (1.3%) | 334 (2.8%) | 401 (8.0%) | <0.001 |
| In-hospital bleeding | 444 (0.3%) | 249 (0.6%) | 163 (1.2%) | <0.001 | 112 (0.3%) | 76 (0.6%) | 57 (1.1%) | <0.001 |

**Table 2:** Crude outcomes by LV function, diabetes and type of diabetes

|  |  |  |
| --- | --- | --- |
| Outcome/adjustment | No diabetes | Diabetes |
| Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV |
| 30-day mortality | 952 (0.6%) | 1,139 (2.9%) | 1,335 (10.2%) | 326 (0.9%) | 438 (3.7%) | 597 (12.0%) |
| In-hospital MACE | 1,898 (1%) | 1,079 (3%) | 1,031 (8%) | 457 (1%) | 334 (3%) | 401 (8%) |
| In-hospital bleeding | 444 (0.3%) | 249 (0.6%) | 163 (1.2%) | 112 (0.3%) | 76 (0.6%) | 57 (1.1%) |

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Diet controlled diabetes | Tablet controlled diabetes | Insulin controlled diabetes |
| Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV |
| 30-day mortality | 326 (0.9%) | 438 (3.7%) | 597 (12.0%) | 160 (0.8%) | 225 (3%) | 294 (11%) | 102 (1%) | 138 (4%) | 187 (13%) |
| In-hospital MACE | 457 (1%) | 334 (3%) | 401 (8%) | 238 (1%) | 177 (3%) | 182 (7%) | 110 (1%) | 102 (3%) | 138 (9%) |
| In-hospital bleeding | 25 (0.3%) | 7 (0.4%) | 7 (0.9%) | 45 (0.2%) | 38 (0.6%) | 26 (1.0%) | 39 (0.5%) | 29 (0.9%) | 20 (1.3%) |

**Table 3a:** Effect of LV function on outcomes for diabetic and non-diabetic patients

|  |  |  |
| --- | --- | --- |
| Outcome/adjustment | No diabetes | Diabetes |
| Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV |
| 30-day mortalityUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 4.85 (4.44-5.29)2.09 (1.90-2.31) | 18.39 (16.89-20.03)4.55 (4.09-5.06) | 1.00 (ref)1.00 (ref) | 4.12 (3.56-4.76)2.03 (1.73-2.38) | 14.57 (12.69-16.74)4.17 (3.52-4.93) |
| In-hospital MACEUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 2.29 (2.12-2.46)1.35 (1.24-1.47) | 6.90 (6.39-7.46)2.24 (2.02-2.47) | 1.00 (ref)1.00 (ref) | 2.21 (1.92-2.55)1.23 (1.05-1.44) | 6.66 (5.80-7.64)1.97 (1.65-2.35) |
| In-hospital bleedingUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 2.23 (1.91-2.60)1.39 (1.17-1.64) | 4.40 (3.67-5.26)1.58 (1.27-1.96) | 1.00 (ref)1.00 (ref) | 2.03 (1.51-2.72)1.18 (0.86-1.62) | 3.63 (2.63-5.00)1.26 (0.86-1.85) |

**Table 3b:** Effect of diabetes on outcomes by LV function group

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Good LV | Moderate LV | Poor LV |
| No diabetes | Diabetes | No diabetes | Diabetes | No diabetes | Diabetes |
| 30-day mortalityUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 1.52 (1.34-1.72)1.62 (1.41-1.86) | 1.00 (ref)1.00 (ref) | 1.29 (1.15-1.44)1.38 (1.21-1.57) | 1.00 (ref)1.00 (ref) | 1.20 (1.09-1.33)1.34 (1.17-1.52) |
| In-hospital MACEUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 1.06 (0.96-1.18)1.01 (0.90-1.12) | 1.00 (ref)1.00 (ref) | 1.03 (0.91-1.17)1.01 (0.88-1.16) | 1.00 (ref)1.00 (ref) | 1.03 (0.91-1.16)1.06 (0.91-1.23) |
| In-hospital bleedingUnadjustedAdjusted | 1.00 (ref)1.00 (ref) | 1.11 (0.91-1.37)1.03 (0.83-1.28) | 1.00 (ref)1.00 (ref) | 1.01 (0.78-1.31)0.98 (0.74-1.29) | 1.00 (ref)1.00 (ref) | 0.92 (0.68-1.25)0.85 (0.61-1.18) |

Adjusted for diagnosis, age, hypertension, hyperlipidaemia, three vessel disease, bare-metal stent, sex, renal disease, previous myocardial infarction, previous PCI, previous CABG, family history of heart disease, smoking status, ventilation, cardiogenic shock, thrombolysis use, intra-aortic balloon pump use, radial access, target vessel and number of stents

**Table 4a:** Effect of LV function by diabetes treatment group

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Diet controlled diabetes (N=9,047) | Tablet controlled diabetes (N=29,800) | Insulin controlled diabetes (N=12,622) |
| Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV | Good LV | Moderate LV | Poor LV |
| Adjusted 30-day mortality | 1.00 (ref) | 1.95 (1.32-2.90) | 5.35 (3.60-7.96) | 1.00 (ref) | 2.19 (1.75-2.75) | 4.34 (3.41-5.52) | 1.00 (ref) | 1.79 (1.34-2.38) | 3.27 (2.41-4.43) |
| Adjusted in-hospital MACE | 1.00 (ref) | 0.87 (0.58-1.29) | 1.93 (1.28-2.90) | 1.00 (ref) | 1.31 (1.06-1.64) | 1.65 (1.27-2.13) | 1.00 (ref) | 1.34 (1.00-1.81) | 2.46 (1.79-3.38) |
| Adjusted in-hospital bleeding | 1.00 (ref) | 0.44 (0.17-1.14) | 0.55 (0.19-1.60) | 1.00 (ref) | 1.62 (1.02-2.59) | 1.86 (1.05-3.28) | 1.00 (ref) | 1.16 (0.70-1.94) | 1.11 (0.59-2.08) |

**Table 4b:** Effect of diabetes treatment groups considering the effect of ejection fraction

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Good LV (N=162,548) | Moderate LV (N=41,156) | Poor LV (N=13,909) |
| No diabetes | Diet control diabetes | No diabetes | Diet control diabetes | No diabetes | Diet control diabetes |
| Adjusted 30-day mortality | 1.00 (ref) | 1.59 (1.20-2.10) | 1.00 (ref) | 1.19 (0.89-1.58) | 1.00 (ref) | 1.51 (1.14-2.01) |
| Adjusted in-hospital MACE | 1.00 (ref) | 1.24 (1.01-1.52) | 1.00 (ref) | 0.83 (0.60-1.14) | 1.00 (ref) | 1.17 (0.84-1.62) |
| Adjusted in-hospital bleeding | 1.00 (ref) | 1.27 (0.84-1.91) | 1.00 (ref) | 0.55 (0.25-1.18) | 1.00 (ref) | 0.73 (0.33-1.61) |

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Good LV (n=176,498) | Moderate LV (n=46,069) | Poor LV (n=15,799) |
| No diabetes | Table controlled diabetes | No diabetes | Table controlled diabetes | No diabetes | Table controlled diabetes |
| Adjusted 30-day mortality | 1.00 (ref) | 1.42 (1.18-1.70) | 1.00 (ref) | 1.33 (1.13-1.57) | 1.00 (ref) | 1.26 (1.07-1.50) |
| Adjusted in-hospital MACE | 1.00 (ref) | 0.91 (0.79-1.05) | 1.00 (ref) | 0.99 (0.83-1.18) | 1.00 (ref) | 0.89 (0.73-1.09) |
| Adjusted in-hospital bleeding | 1.00 (ref) | 0.74 (0.54-1.02) | 1.00 (ref) | 0.90 (0.63-1.29) | 1.00 (ref) | 0.79 (0.51-1.22) |

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome/adjustment | Good LV (n=163,876) | Moderate LV (n=42,678) | Poor LV (n=14,634) |
| No diabetes | Insulin controlled diabetes | No diabetes | Insulin controlled diabetes | No diabetes | Insulin controlled diabetes |
| Adjusted 30-day mortality | 1.00 (ref) | 2.09 (1.66-2.65) | 1.00 (ref) | 1.56 (1.26-1.93) | 1.00 (ref) | 1.40 (1.13-1.74) |
| Adjusted in-hospital MACE | 1.00 (ref) | 1.02 (0.83-1.26) | 1.00 (ref) | 1.10 (0.87-1.38) | 1.00 (ref) | 1.30 (1.03-1.64) |
| Adjusted in-hospital bleeding | 1.00 (ref) | 1.41 (1.00-2.00) | 1.00 (ref) | 1.33 (0.88-2.02) | 1.00 (ref) | 0.86 (0.51-1.44) |

Adjusted for diagnosis, age, hypertension, hyperlipidaemia, three vessel disease, bare-metal stent, sex, renal disease, previous myocardial infarction, previous PCI, previous CABG, family history of heart disease, smoking status, ventilation, cardiogenic shock, thrombolysis use, intra-aortic balloon pump use, radial access, target vessel and number of stents.